[ad_1]
New York, July 8, 2021 (Global News Agency)-Reportlinker.com announced the release of the report “Somatostatin Analogue Market Research Report by Type, Application, and Region-Global Forecast to 2026-COVID-19 Cumulative impact of “- https://www.reportlinker.com/p06087977/?utm_source=GNW
The global somatostatin analogue market in 2020 is estimated to be USD 5.122.1 billion, and is expected to reach USD 5.63227 billion by 2021. The compound annual growth rate (CAGR) from 2020 to 2026 is 10.29%, and it will reach 922.2824 million by 2026 US dollars.
Market Statistics:
The report provides market sizes and forecasts for the five major currencies (USD, Euro, British Pound, Japanese Yen and Australian Dollar). When currency exchange data is readily available, it can help organizational leaders make better decisions. This report uses 2018 and 2019 as the historical years, 2020 as the base year, 2021 as the estimated year, and 2022-2026 as the forecast period.
Market segmentation and coverage:
This research report categorizes somatostatin analogs to predict revenue and analyze trends in each of the following sub-markets:
Based on the type, the market for somatostatin analogs of lanreotide, octreotide and pasireotide was studied.
Based on the application program, the market of somatostatin analogs for acromegaly and neuroendocrine tumors was studied.
Based on geography, researched the somatostatin analogue market in the Americas, Asia-Pacific region and Europe, Middle East and Africa. The Americas have been further studied in Argentina, Brazil, Canada, Mexico and the United States. Further researched the Asia-Pacific region in China, India, Indonesia, Japan, Malaysia, the Philippines, South Korea and Thailand. Europe, the Middle East, and Africa conducted further studies in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, the United Arab Emirates, and the United Kingdom.
The cumulative effect of
The full story on Benzinga.com
[ad_2]
Source link
